Blood pressure (BP) is controlled only in 34% of Americans with hypertension. 1 Barriers to control include patient nonadherence or inadequate access to care. New data suggest, however, that these are not the most important causes of poor BP control. Two studies found that most cases of uncontrolled hypertension occur in patients who had frequent contact with physicians. 2,3 These results suggest investigation of the premise that BP is not aggressively treated even when physicians frequently see patients with hypertension. Another study assessed reasons for poor BP control and found patient factors (adherence, patient acceptance, regimen complexity) were uncommon (9%) barriers cited by physicians or patients. 4 The primary barrier (91% of patient visits) was related to physicians who were satisfied with poorly controlled BP. As clinicians, many of us have seen patients who have difficulty with medication adherence or accessing the healthcare system. However, these recent findings suggest that physicians' decisions and behavior may be more important factors contributing to poor BP control. New models for delivering care, such as the one described by Chabot et al. 5 in this issue of The Annals, must be further developed and tested.
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Several studies have found that community pharmacists can improve BP control when they focus on patient management. 6-8 There have been even greater numbers of trials conducted in organized healthcare settings where the pharmacist is an integral member of the practice. 6,9-12 While these studies had positive results, the pharmacy literature has been criticized for including those with small sample sizes, design flaws, lack of control groups, incorrect analyses, and no evaluation of covariates that might influence outcomes. 13, 14 Most of the evaluations of treatment of hypertension suffered from at least 1 of these problems. Some problems may be understandable, since pharmacy practice research is maturing and historically has not been well funded by external agencies.
The studies noted above were usually very focused, involving only a few pharmacists and 1 or 2 clinical sites.
Thus, the results are difficult to generalize to other settings. It is easier to implement an intervention with small numbers of highly motivated providers. When pharmacy practice research has involved multiple sites, there has been incomplete delivery of the intervention by some pharmacists. [15] [16] [17] Several studies have found that many pharmacists simply did not complete all aspects of the intervention or did not provide any intervention. Time constraints and inadequate payment have been cited as barriers. While the incomplete implementation of pharmacy interventions is a serious indictment of the profession, these findings also have important research implications for research design and data analysis.
Chabot et al. 5 conducted a pilot study of 100 hypertensive patients receiving care from 9 community pharmacies in Quebec. There were 4 pharmacies in the intervention group and 5 in a usual care group. The pharmacies were not randomized and the intervention pharmacies volunteered to perform the intervention, which may have resulted in more motivated pharmacists in the intervention group. The fees that these pharmacists received were modest and much lower than in other community pharmacy intervention studies. 17 A positive design feature was that data and BP readings were collected by blinded research assistants in the patients' homes.
The intriguing finding from this study was that pharmacy intervention was effective only for patients with high incomes. In fact, it appears that patients with low incomes did worse in the intervention group compared with the control group, but the sample size is too small for appropriate statistical comparisons. It has been known for some time that patients in lower socioeconomic groups have a much higher risk for a wide variety of diseases. Increases in systolic BP over a 9-year period were greater in patients from lower compared with higher socioeconomic groups. 18 This and other information imply that it may be more difficult to control BP in patients who are socioeconomically disadvantaged. Whether this finding is due to lower educational levels, nonadherence, or the simple fact that these patients must deal with far more pressing day-to-day survival matters than worry about their BP requires further in-vestigation. Chabot et al. found that the lower income group achieved little, if any, reduction in systolic BP, regardless of intervention. Can these findings be attributed to differences in income? While this is a very intriguing hypothesis that requires further study, there are several reasons why this may not be the case.
The intervention was implemented more frequently in patients with high income than those with low income (38% vs. 25%, respectively). While the pharmacist made more contacts with low-income patients compared with those with high income (6.5 vs. 4.8, respectively), the number of interventions per patient was fewer (1.5 vs. 1.8, respectively). Eight patients with low income (36%) did not receive any intervention compared with 3 patients with high income (23%). More patients in the high-income group reported to be adherent to their therapy than those with low incomes, but this too could be related to less attention and education being provided to patients with lower incomes. The authors suggest that the intervention may have "stimulated high-income patients to take more responsibility for management of their condition." We believe their findings could imply a systematic bias against providing the intervention for patients with low incomes. Specifically, time was mentioned as a reason for lack of program implementation. It is possible that pharmacists perceived a larger time requirement to provide intervention for low-income patients. Likewise, lack of interest in the program was also mentioned as a barrier to implementing the program. Consequently, patients with low incomes may have been more likely to refuse the intervention. We have no evidence that either of these biases occurred. In either case, the results might not be due to what the pharmacists did, but for whom they provided the intervention. We suspect that if the data had not been analyzed for income separately, the intervention would have had no statistically significant effect. The big question is: Are the authors really measuring the effect of income or is income a surrogate measure of the intensity of the intervention that pharmacists provided?
While we commend Chabot et al. for evaluating a new model of hypertension care, we are not convinced, as the methods state, that these pharmacists are providing pharmaceutical care. In this study, intervention pharmacies provided "pharmaceutical care" with the assistance of a computer decision tool. However, details of the care that was provided were not well described. Only 11% of patients were referred to their physician and only 2 (5.7%) patients' physicians received a recommendation to increase treatment. The vast majority of actual interventions involved patient education. While education and counseling are critical to patient management, these are not the hallmarks of pharmaceutical care. Pharmaceutical care involves identifying and resolving drug-related problems and doing whatever it takes to solve these problems. One of the most common drug-related problems is suboptimal treatment or absence of a needed medication. 15,17 A more potent intervention that required pharmacists to make recommendations to physicians and/or provide direct patient management may have produced more dramatic results, independent of income.
Finally, many patients in the study by Chabot et al. had controlled BP at baseline. An intervention designed to efficiently use the expertise of pharmacists should focus on patients with uncontrolled hypertension where the overall effect of the intervention would likely be greater.
However, one of us (BLC) must acknowledge some of these problems with his studies, often due to limited sources of adequate funding. Our comments should also not detract from 2 critical issues from Chabot et al.'s study: it is quite possible that pharmacy interventions are more effective in some patients than others, and when pharmacists do not fully implement an intervention, we must account for that in the analysis. To that extent, we can all learn something as we consider designing future pharmacy intervention studies. This leads us to several recommendations:
1. Patients should generally be included in a hypertension intervention study only if they have uncontrolled BP. While it is important to provide maintenance support for all patients, the most efficient use of an expensive pharmacy intervention would be to focus on those with poor control.
2. Future pharmacy intervention studies for patients with hypertension should be of sufficient size to control for and assess the effects of covariates such as (1) within-and between-patient variability, (2) between-physician variability, (3) between-clinic (pharmacy) variability, and (4) patient adherence, age, gender, race, income or economic status, weight (body mass index), activity, diet, coexisting conditions, and antihypertensive medications. Evaluating all of these covariates will require a large sample size and, generally, a substantial budget.
3. Research must carefully define, implement, and measure the intervention. In the case of interventions for hypertension, studies must be designed to influence physician behavior since this is one of the most frequent causes for poor BP control. An intervention that focuses strictly on providing patient education and information will not be fully effective if the patient is receiving suboptimal therapy.
4. Features of the intervention must allow adequate time, personnel, and payment for pharmacists to deliver care.
5. An intervention that is incompletely delivered by the pharmacist or incompletely implemented by the patient must be evaluated by using intent-to-treat analysis followed by an instrumental variables analysis. 19-21 The latter is a method to account for uneven or incomplete adherence to the intervention (in this case, by the pharmacist) and to assess where the intervention can be most effective.
Studies such as the one by Chabot et al. are important because they provide us with hypotheses to test and features to consider in future trials. The fact that there may be difficulties with interpreting these findings is understandable from a pilot study not designed to test the effect of an intervention on different economic groups. The authors are to be commended for exploring one variable that may have influenced the outcome of this intervention. The design of pharmacy intervention studies must include variables that may influence the outcome and be capable of measuring and controlling for these variables.
